From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Videos|September 11, 2017
The Growing Opioid Abuse Epidemic: What Factors Are Playing a Role?
In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses why opioid abuse has become an increasingly urgent issue.
Advertisement
In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses why opioid abuse has become an increasingly urgent issue.
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5